{"type":"trials","record":{"id":41819,"source_id":"clinicaltrials-gov","external_id":"NCT04764656","title":"Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal","brief_summary":"This study is a prospective, observational, non-interventional, multicenter, open-label, single arm study in patients being treated for nAMD with brolucizumab in Portugal.","overall_status":"Terminated","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Novartis Pharmaceuticals","enrollment":81,"countries":["Portugal"],"start_date":"2021-05-10","completion_date":"2024-02-16","last_update_date":"2025-03-25","source_url":"https://clinicaltrials.gov/study/NCT04764656","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"BLUESKY-PT","age_range":"40 Years to 110 Years","comparator":null,"organization":"Novartis","interventions":["Brolucizumab"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Percentage of patients that are absent of subretinal fluid (SRF) and intra-retinal fluid (IRF) in the study eye — month…","Fluid resolution after initiation of brolucizumab — month 24","Visual Actuity (VA) change from baseline — Baseline, month 24","Characterize Choroidal Neovascularization (CNV) morphology (BIRL) and activity — month 24","Number of injections and total number of visits — month 24","Describe the distribution of injection intervals — month 24","Number of Spectral Contrast Optical Coherence Tomography (SC-OCTs) done — month 24","Characterize the patients switching to another antivascular endothelial growth factor (anti-VEGF) — month 24","Discontinuation rate — month 24","Assess the safety of brolucizumab — month 24"],"design_description":null,"source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration (nAMD)","Brolucizumab"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04764656","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2021-05-10 to 2024-02-16","comparator":null,"confidence":"structured-source","population":"ALL · 40 Years to 110 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.876Z","intervention":["Brolucizumab"],"participants":81,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Percentage of patients that are absent of subretinal fluid (SRF) and intra-retinal fluid (IRF) in the study eye — month…","Fluid resolution after initiation of brolucizumab — month 24","Visual Actuity (VA) change from baseline — Baseline, month 24","Characterize Choroidal Neovascularization (CNV) morphology (BIRL) and activity — month 24","Number of injections and total number of visits — month 24","Describe the distribution of injection intervals — month 24","Number of Spectral Contrast Optical Coherence Tomography (SC-OCTs) done — month 24","Characterize the patients switching to another antivascular endothelial growth factor (anti-VEGF) — month 24","Discontinuation rate — month 24","Assess the safety of brolucizumab — month 24"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41819","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}